This is an unofficial archive of PsychonautWiki as of 2025-08-08T03:33:20Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
Substance P: Difference between revisions
>Oskykins m Text replacement - "==See also==" to "==See also== *Responsible use" |
>Josikins m Text replacement - " | http://www.ncbi." to " (PubMed.gov / NCBI) | http://www.ncbi." |
||
| Line 42: | Line 42: | ||
There is ample circumstantial evidence that elevated SP is involved in reactions to stress and the regulation of mood.<ref name="mood" /> These include the presence of NK1 receptors in emotion centers like the amygdala and the association of SP-neurons with serotonergic or noradrenergic neurons; both serotonin and norepinephrine are heavily implicated in mood order and disorders like anxiety and depression. Elsewhere in the nervous system, SP associates with [[glutamate]], particularly the [[NMDA]] receptor. Disruptions of the glutamatergic system have recently been explored for their possible causal role in mood disorders. | There is ample circumstantial evidence that elevated SP is involved in reactions to stress and the regulation of mood.<ref name="mood" /> These include the presence of NK1 receptors in emotion centers like the amygdala and the association of SP-neurons with serotonergic or noradrenergic neurons; both serotonin and norepinephrine are heavily implicated in mood order and disorders like anxiety and depression. Elsewhere in the nervous system, SP associates with [[glutamate]], particularly the [[NMDA]] receptor. Disruptions of the glutamatergic system have recently been explored for their possible causal role in mood disorders. | ||
Attempts have been made to create anxiolytic and antidepressant drugs out of SP antagonists. Several phase I and II trials of NK1 antagonists, including aprepitant, showed significant antidepressant and anxiolytic activity in depressed patients. However, subsequent phase III trials failed to replicate the findings, and no antidepressant with a mechanism of action related to Substance P has been brought to market.<ref name="psychiatry">Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential | http://www.ncbi.nlm.nih.gov/pubmed/15813642</ref> | Attempts have been made to create anxiolytic and antidepressant drugs out of SP antagonists. Several phase I and II trials of NK1 antagonists, including aprepitant, showed significant antidepressant and anxiolytic activity in depressed patients. However, subsequent phase III trials failed to replicate the findings, and no antidepressant with a mechanism of action related to Substance P has been brought to market.<ref name="psychiatry">Substance P receptor antagonists in psychiatry: rationale for development and therapeutic potential (PubMed.gov / NCBI) | http://www.ncbi.nlm.nih.gov/pubmed/15813642</ref> | ||
Male knockout mice were significantly less aggressive when faced with an invasion of their territory compared to wild-type mice, indicating a role in modulating social function.<ref name="stress" /> | Male knockout mice were significantly less aggressive when faced with an invasion of their territory compared to wild-type mice, indicating a role in modulating social function.<ref name="stress" /> | ||